Date: Sunday, November 7, 2021
Session Type: Poster Session B
Session Time: 8:30AM-10:30AM
Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) includes achieving remission or at least low disease activity within six months of starting therapy. Active RA may be treated with either biological DMARDs (bDMARDs) or JAK inhibitors after inefficacy or intolerance of conventional DMARDs. To date, only few data are available on the persistence of the different treatment approaches in daily practice.
Methods: Regarding different mode of actions (MoA) for anti-rheumatic treatment, this analysis compares the persistence of JAK inhibitors with TNF inhibitors and other bDMARDs (nonTNFi) in RA patients from the German RheumaDatenRhePort (Rhadar) registry.
Data of 5154 RA patients from the pseudonymized Rhadar registry (Kleinert, S., P. Bartz-Bazzanella et. al. (2021). “A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry.” J Med Internet Res 23(5): e28164.) entered by 22 rheumatologists were evaluated. Patients were included in the sample characterization if at least one registry entry was documented between July 1st, 2020, and March 31st, 2021. Only data of those patients that received a newly prescribed bDMARD or JAK inhibitor between June 1st, 2017 (shortly after the approval of tofacitinib and baricitinib in Germany) and March 31st, 2020, were compared regarding persistence. 3124 (60,6 %) of the evaluated patients suffered from a seropositive RA, 73,5% females, with a mean age of 64.5±13.9 years. 66.9% received monotherapy. The persistence of the respective MoA was calculated using Kaplan-Meier survival curves. Descriptive statistical analysis and drug survival were calculated using R (version 4.0.4) (R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2018) and RStudio (version 1.4.1103) (RStudio Team. RStudio: Integrated Development for R. RStudio, Inc, Boston, MA. 2016).
Results: Prescription information of 4715 of the 5154 patients was available at database closure. Of these 4715 patients, 15.2% received a TNF inhibitor, 8.9% other bDMARDs and 10.0% a JAK inhibitor. JAK inhibitors were prescribed as monotherapy in 64.8%, TNF inhibitors only in 45.4% and other bDMARDs in 63.7% of the RA patients. The persistence on JAK inhibitors, TNF inhibitors and other bDMARDs was high ( > 85% after 24 months) (fig. 1) and did not differ significantly between JAK inhibitors and TNF inhibitors (p = 0.724) or JAK inhibitors and other bDMARDs (p = 0.084) in a corresponding Cox proportional hazards model.
Conclusion: The persistence of therapy with JAK-inhibitors is high in daily practice, comparable to TNF inhibitors and other bDMARDs.
To cite this abstract in AMA style:Risser L, Witte T, Bartz-Bazzanella P, Von der Decken C, Knitza J, Fekete S, Zink A, Gauler G, Wurth P, Aries P, Karberg K, Kuhn C, Schuch F, Späthling-Mestekemper S, Vorbrüggen W, Englbrecht M, Welcker M, Kleinert S. Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10). https://acrabstracts.org/abstract/persistence-on-jak-inhibitors-in-daily-practice-evaluation-of-the-rhadar-registry/. Accessed January 27, 2022.
« Back to ACR Convergence 2021
ACR Meeting Abstracts - https://acrabstracts.org/abstract/persistence-on-jak-inhibitors-in-daily-practice-evaluation-of-the-rhadar-registry/